Open Label Extension to Bridging Study CTBM100C2303

clinical trial

MedicalStudy clinical_trial Q64662776

Press Enter · cited answer in seconds

Summary

Open Label Extension to Bridging Study CTBM100C2303 is a clinical trial^[1].

Key Facts

Open Label Extension to Bridging Study CTBM100C2303 is in the country of Estonia^[2].
Open Label Extension to Bridging Study CTBM100C2303's instance of is recorded as clinical trial^[3].
Open Label Extension to Bridging Study CTBM100C2303's start time is recorded as +2009-08-31T00:00:00Z^[4].
Open Label Extension to Bridging Study CTBM100C2303's end time is recorded as +2011-10-31T00:00:00Z^[5].
Open Label Extension to Bridging Study CTBM100C2303's sponsor is recorded as Novartis^[6].
Open Label Extension to Bridging Study CTBM100C2303's main subject is recorded as cystic fibrosis^[7].
Open Label Extension to Bridging Study CTBM100C2303's main subject is recorded as antibiotic^[8].
Open Label Extension to Bridging Study CTBM100C2303's number of participants is recorded as {'unit': '1', 'amount': '+57'}^[9].
Open Label Extension to Bridging Study CTBM100C2303's title is recorded as A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.^[10].
Open Label Extension to Bridging Study CTBM100C2303's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+6'}^[11].
Open Label Extension to Bridging Study CTBM100C2303's ClinicalTrials.gov ID is recorded as NCT00982930^[12].
Open Label Extension to Bridging Study CTBM100C2303's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+21'}^[13].
Open Label Extension to Bridging Study CTBM100C2303's research intervention is recorded as tobramycin^[14].
Open Label Extension to Bridging Study CTBM100C2303's clinical trial phase is recorded as phase III clinical trial^[15].
Open Label Extension to Bridging Study CTBM100C2303's research site is recorded as Novartis^[16].
Open Label Extension to Bridging Study CTBM100C2303's study type is recorded as interventional study^[17].

⭐ Popularity Graph

0/100 long tail

⛏️ Lake Facts · open-dataset statements via 4ort-mint

From open datasets, joined by identifier and shown only for properties Wikidata does not state on this entity — except where the dataset is the registry authority for the fact (ClinicalTrials.gov on trial registration data): there its value is shown instead, with Wikidata's noted beside it. Every row carries its dataset edition and licence.

Number of participantsP1132

55 (ACTUAL) 2026-09-26 Wikidata lists 57 ClinicalTrials.gov (US Government Public Domain)

Start timeP580

2009-08-12 2026-09-26 Wikidata lists 2009-08-31 ClinicalTrials.gov (US Government Public Domain)

End timeP582

2011-10-06 2026-09-26 Wikidata lists 2011-10-31 ClinicalTrials.gov (US Government Public Domain)

Medical conditionP1050

cystic fibrosis 2026-09-26 ClinicalTrials.gov (US Government Public Domain)

ClinicalTrials.gov (data processed by ClinicalTrials.gov on 2026-09-26); U.S. federal government data, public domain; lake licence_code custom-review

Quick Facts

Instance of clinical trial

Country Estonia

Properties

Clinical trial phase phase III clinical trial

End time October 31, 2011

Imported from wholeness_audit_2026-05-02

Main subject cystic fibrosis, antibiotic

Maximum age 21 year

Minimum age 6 year

Number of participants 57

Research intervention tobramycin

Research site Novartis

Sponsor Novartis

Start time August 31, 2009

Study type interventional study

Title A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.

External References (1)

Clinicaltrials.gov id NCT00982930

🏷️ Also known as

en Open Label Extension to Bridging Study CTBM100C2303

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

Class ancestry

[1] ↑ Open Label Extension to Bridging Study CTBM100C2303 is an instance of clinical trial (Q30612) [P31, primary]. Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA

4ort.xyz Knowledge Graph. (2026). Open Label Extension to Bridging Study CTBM100C2303. Retrieved May 3, 2026, from https://4ort.xyz/entity/open-label-extension-to-bridging-study-ctbm100c2303

MLA

“Open Label Extension to Bridging Study CTBM100C2303.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/open-label-extension-to-bridging-study-ctbm100c2303.

BibTeX

@misc{4ortxyz_open-label-extension-to-bridging-study-ctbm100c2303_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Open Label Extension to Bridging Study CTBM100C2303}}, year = {2026}, url = {https://4ort.xyz/entity/open-label-extension-to-bridging-study-ctbm100c2303}, note = {Accessed: 2026-05-03}}

LLM prompt

According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Open Label Extension to Bridging Study CTBM100C2303 — https://4ort.xyz/entity/open-label-extension-to-bridging-study-ctbm100c2303 (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/open-label-extension-to-bridging-study-ctbm100c2303 · Last refreshed: May 3, 2026